(2S)-2-[(2-hydroxyacetyl)amino]-3-(4-hydroxyphenyl)propanoic acid | 172723-44-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-[(2-hydroxyacetyl)amino]-3-(4-hydroxyphenyl)propanoic acid
• CAS: 172723-44-3
• 化学式: C₁₁H₁₃NO₅
• 分子量: 239.228
• InChiKey: HFBZCKJQEQLCAZ-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-(2-benzyloxy-acetylamino)-3-[4-(2-hydroxy-acetoxy)-phenyl]-propionic acid methoxycarbonylmethyl ester 反应 1.0h， 生成 (2S)-2-[(2-hydroxyacetyl)amino]-3-(4-hydroxyphenyl)propanoic acid
  参考文献：
  名称：

  WO2007/47244

  摘要：

  公开号：

文献信息

• Molecular vaccines for infectious disease
  申请人：Schøller Jørgen

  公开号：US10369204B2

  公开（公告）日：2019-08-06

  The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.

  本发明涉及构建药剂的方法，即以其多聚化结构域和所附生物活性分子为特征的疫苗成分，以及将其用于制备单独含有药剂或与其他分子结合的疫苗。构建体的各个分子可以通过共价键或非共价键，直接或通过连接体相互结合或与多聚化结构域结合。本发明进一步涉及此类制剂在疫苗中的使用，旨在作为人类和动物的预防/预防性或治疗性疫苗。
• MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
  申请人：Schøller Jørgen

  公开号：US10611818B2

  公开（公告）日：2020-04-07

  The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising Mycobacterium tuberculosis antigenic peptides and uses there of.

  本发明涉及 MHC 肽复合物及其在个体疾病诊断、治疗或疫苗接种中的用途。更具体地说，本发明公开了包含结核分枝杆菌抗原肽的 MHC 复合物及其用途。
• MHC multimers in borrelia diagnostics and disease
  申请人：Schøller Jørgen

  公开号：US10968269B1

  公开（公告）日：2021-04-06

  Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.

  本研究公开了携带能与相关靶细胞上的反受体结合的配体的新型化合物。这些化合物具有许多有利特征，因此非常适合广泛应用，包括用作检测系统、检测相关靶细胞以及许多其他方法。特别是，本研究公开了新型 MHC 复合物，该复合物由一个或多个 MHC 分子组成，其中包含一个或多个源自包柔氏菌的肽。向靶细胞呈现多种 MHC 肽复合物的可能性使本发明的 MHC 复合物成为治疗和诊断等领域极为强大的工具。本发明一般涉及 MHC 复合物和 MHC 多聚物的样品安装使用。 本发明还涉及治疗和疫苗领域，包括治疗/疫苗方法和治疗/疫苗组合物。
• MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS
  申请人：Dako Denmark A/S

  公开号：EP2197908A2

  公开（公告）日：2010-06-23
• MHC MULTIMERS IN BORRELIA DIAGNOSTICS AND DISEASE
  申请人：Dako Denmark A/S

  公开号：EP2254592A2

  公开（公告）日：2010-12-01